

# Nicole Lamanna

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/9927459/nicole-lamanna-publications-by-year.pdf>

**Version:** 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

125  
papers

4,004  
citations

24  
h-index

62  
g-index

133  
ext. papers

4,843  
ext. citations

4.2  
avg, IF

4.78  
L-index

#	Paper	IF	Citations
125	Comparative analysis of targeted novel therapies in relapsed, refractory chronic lymphocytic leukaemia. <i>Haematologica</i> , <b>2021</b> , 106, 284-287	6.6	1
124	A multicenter, retrospective study of accelerated venetoclax ramp-up in patients with relapsed/refractory chronic lymphocytic leukemia.. <i>American Journal of Hematology</i> , <b>2021</b> ,	7.1	1
123	Addressing a New Challenge in Chronic Lymphocytic Leukemia: Outcomes of Therapies after Exposure to Both a Covalent Bruton $\beta$ Tyrosine Kinase Inhibitor and Venetoclax. <i>Blood</i> , <b>2021</b> , 138, 2628-2628	2.2	5
122	Phase 1b/2 Study of Cirmtuzumab and Ibrutinib in Mantle Cell Lymphoma (MCL) or Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , <b>2021</b> , 138, 3534-3534	2.2	0
121	Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study. <i>Lancet, The</i> , <b>2021</b> , 397, 892-901	4.0	81
120	Phase 1/2 study of cirmtuzumab and ibrutinib in mantle cell lymphoma (MCL) or chronic lymphocytic leukemia (CLL).. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 7556-7556	2.2	2
119	Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3K $\gamma$ inhibitor therapy. <i>Blood</i> , <b>2021</b> , 137, 2817-2826	2.2	19
118	Smudge Cells in Chronic Lymphocytic Leukemia: Pathophysiology, Laboratory Considerations, and Clinical Significance. <i>Laboratory Medicine</i> , <b>2021</b> , 52, 426-438	1.6	2
117	COVID-19 in patients with CLL: improved survival outcomes and update on management strategies. <i>Blood</i> , <b>2021</b> , 138, 1768-1773	2.2	12
116	Case Presentation [Relapse After Frontline BTKi Therapy in Patients with CLL: Options and Consideration. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2021</b> , 21, S40-S42	2	
115	Targeting CD38 is lethal to Breg-like chronic lymphocytic leukemia cells and Tregs, but restores CD8+ T-cell responses. <i>Blood Advances</i> , <b>2020</b> , 4, 2143-2157	7.8	14
114	Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 3589-3596	12.9	43
113	Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL in the DUO Crossover Extension Study. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 2096-2103	12.9	18
112	ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. <i>Future Oncology</i> , <b>2020</b> , 16, 517-523	3.6	23
111	Is There a Role for Chemotherapy in the Era of Targeted Therapies?. <i>Current Hematologic Malignancy Reports</i> , <b>2020</b> , 15, 72-82	4.4	2
110	The Connect CLL Registry: final analysis of 1494 patients with chronic lymphocytic leukemia across 199 US sites. <i>Blood Advances</i> , <b>2020</b> , 4, 1407-1418	7.8	3
109	Cirmtuzumab, an Anti-ROR1 Antibody, in Combination with Ibrutinib: Clinical Activity in Mantle Cell Lymphoma (MCL) or Chronic Lymphocytic Leukemia (CLL) from a Phase 1/2 Study. <i>Blood</i> , <b>2020</b> , 136, 45-46	2.2	4

108	Clinical activity of cirmtuzumab, an anti-ROR1 antibody, in combination with ibrutinib: Interim results of a phase Ib/II study in mantle cell lymphoma (MCL) or chronic lymphocytic leukemia (CLL).. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 8036-8036	2.2	1
107	The efficacy and safety of venetoclax therapy in elderly patients with relapsed, refractory chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , <b>2020</b> , 188, 918-923	4.5	10
106	Outcomes of COVID-19 in patients with CLL: a multicenter international experience. <i>Blood</i> , <b>2020</b> , 136, 1134-1143	2.2	132
105	Risk factors for grade 3/4 transaminase elevation in patients with chronic lymphocytic leukemia treated with idelalisib. <i>Leukemia</i> , <b>2020</b> , 34, 3404-3407	10.7	2
104	Managing toxicities of Bruton tyrosine kinase inhibitors. <i>Hematology American Society of Hematology Education Program</i> , <b>2020</b> , 2020, 336-345	3.1	28
103	Longitudinal health-related quality of life in first-line treated patients with chronic lymphocytic leukemia: Results from the Connect CLL Registry. <i>EJHaem</i> , <b>2020</b> , 1, 188-198	0.9	1
102	Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study. <i>Cancer Medicine</i> , <b>2020</b> , 9, 8468-8479	4.8	8
101	The Impact of Age on Survival in CLL Patients Receiving Ibrutinib as Initial Therapy. <i>Blood and Lymphatic Cancer: Targets and Therapy</i> , <b>2020</b> , 10, 1-5	2.6	1
100	Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 1391-1402	2.2	109
99	Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 4264-4270	12.9	37
98	Clonal diversity predicts adverse outcome in chronic lymphocytic leukemia. <i>Leukemia</i> , <b>2019</b> , 33, 390-402	10.7	30
97	Efficacy of Therapies Following Venetoclax Discontinuation in CLL: Focus on B-Cell Receptor Signal Transduction Inhibitors and Cellular Therapies. <i>Blood</i> , <b>2019</b> , 134, 502-502	2.2	4
96	Four-Year Analysis of Murano Study Confirms Sustained Benefit of Time-Limited Venetoclax-Rituximab (VenR) in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , <b>2019</b> , 134, 355-355	2.2	13
95	Toxicities and Outcomes of Acalabrutinib-Treated Patients with Chronic Lymphocytic Leukemia: A Retrospective Analysis of Real World Patients. <i>Blood</i> , <b>2019</b> , 134, 4311-4311	2.2	12
94	Effect of dose modifications on response to duvelisib in patients with relapsed/refractory (R/R) CLL/SLL in the DUO trial.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 7523-7523	2.2	4
93	Combination Thioguanine and Decitabine Is Highly Active in Patients with Advanced Myeloid Malignancies: A Single Institution Experience. <i>Blood</i> , <b>2019</b> , 134, 3899-3899	2.2	
92	Evolution in Practice Patterns and Differences Among Experts and Community Healthcare Providers in the Treatment of Patients with Chronic Lymphocytic Leukemia. <i>Blood</i> , <b>2019</b> , 134, 4724-4724	2.2	
91	Cirmtuzumab, a ROR1 Targeted Mab, Reverses Cancer Stemness, and Its Combination with Ibrutinib Is Safe and Effective: Planned Analysis of the Cirll Phase 1/2 Trial for CLL and MCL. <i>Blood</i> , <b>2019</b> , 134, 1755-1755	2.2	1

90	Alpine: Phase 3 Trial of Zanubrutinib (BGB-3111) Vs Ibrutinib in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL). <i>Blood</i> , <b>2019</b> , 134, 4307-4307	2.2	1
89	A retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibody in R/R CLL. <i>Blood Advances</i> , <b>2019</b> , 3, 1568-1573	7.8	18
88	Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis. <i>Haematologica</i> , <b>2018</b> , 103, 874-879	6.6	219
87	Reasons for initiation of treatment and predictors of response for patients with Rai stage 0/1 chronic lymphocytic leukemia (CLL) receiving first-line therapy: an analysis of the Connect CLL cohort study. <i>Leukemia and Lymphoma</i> , <b>2018</b> , 59, 2327-2335	1.9	3
86	Prognostic Testing Patterns and Outcomes of Chronic Lymphocytic Leukemia Patients Stratified by Fluorescence In Situ Hybridization/Cytogenetics: A Real-world Clinical Experience in the Connect CLL Registry. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2018</b> , 18, 114-124.e2	2	16
85	Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trial. <i>American Journal of Hematology</i> , <b>2018</b> , 93, 1394-1401	7.1	37
84	Autologous CD19-Targeted CAR T Cells in Patients with Residual CLL following Initial Purine Analog-Based Therapy. <i>Molecular Therapy</i> , <b>2018</b> , 26, 1896-1905	11.7	46
83	Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States. <i>Haematologica</i> , <b>2018</b> , 103, 1511-1517	6.6	91
82	MURANO Trial Establishes Feasibility of Time-Limited Venetoclax-Rituximab (VenR) Combination Therapy in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , <b>2018</b> , 132, 184-184	2.2	7
81	Minimal Residual Disease Status with Venetoclax Monotherapy Is Associated with Progression-Free Survival in Chronic Lymphocytic Leukemia. <i>Blood</i> , <b>2018</b> , 132, 3134-3134	2.2	3
80	Venetoclax As Monotherapy or in Combination: Patterns of Use and Predictors of Outcomes in an International Multicenter Study of CLL Patients. <i>Blood</i> , <b>2018</b> , 132, 3142-3142	2.2	2
79	The Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL: Updated Results from the DUO Crossover Extension Study. <i>Blood</i> , <b>2018</b> , 132, 3140-3140	2.2	1
78	Duvelisib inhibition of chemokines in patients with CLL (DUO study) and iNHL (DYNAMO study).. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 12048-12048	2.2	1
77	A phase 2 study to assess the safety and efficacy of umbralisib (TGR-1202) in pts with CLL who are intolerant to prior BTK or PI3K inhibitor therapy.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 7530-7530	2.2	5
76	The efficacy of duvelisib monotherapy following disease progression on ofatumumab monotherapy in patients with relapsed/refractory CLL or SLL in the DUO crossover extension study.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 7533-7533	2.2	1
75	Racial, age, and sex disparities in chronic lymphocytic leukemia (CLL) patients treated with novel therapies.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 6577-6577	2.2	
74	Adverse Events, Patterns of Tumor Lysis Syndrome Prophylaxis and Management, and Dosing Patterns in a Large Cohort of Venetoclax Treated CLL Patients in Community and Academic Settings. <i>Blood</i> , <b>2018</b> , 132, 4410-4410	2.2	
73	Treatment Patterns and Outcomes of Patients with CLL Treated with Chemoimmuno- and Novel Agent-Based Therapy: A Multicenter Study. <i>Blood</i> , <b>2018</b> , 132, 4759-4759	2.2	0

72	Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. <i>Lancet Oncology, The</i> , <b>2018</b> , 19, 65-75	21.7	228
71	The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL. <i>Blood</i> , <b>2018</b> , 132, 2446-2455	2.2	184
70	Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients. <i>Annals of Oncology</i> , <b>2017</b> , 28, 1050-1056	10.3	139
69	Characterizing and prognosticating chronic lymphocytic leukemia in the elderly: prospective evaluation on 455 patients treated in the United States. <i>BMC Cancer</i> , <b>2017</b> , 17, 198	4.8	7
68	Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia with Novel Targeted Agents. <i>Oncologist</i> , <b>2017</b> , 22, 1283-1291	5.7	39
67	Early progression of disease as a predictor of survival in chronic lymphocytic leukemia. <i>Blood Advances</i> , <b>2017</b> , 1, 2433-2443	7.8	7
66	KI intolerance study: A phase 2 study to assess the safety and efficacy of TGR-1202 in pts with chronic lymphocytic leukemia (CLL) who are intolerant to prior BTK or PI3K-delta inhibitor therapy.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, TPS7569-TPS7569	2.2	
65	Real-world clinical experience in the Connect chronic lymphocytic leukaemia registry: a prospective cohort study of 1494 patients across 199 US centres. <i>British Journal of Haematology</i> , <b>2016</b> , 175, 892-903	4.5	37
64	Evolving Strategies for the Treatment of Chronic Lymphocytic Leukemia in the Upfront Setting. <i>Current Hematologic Malignancy Reports</i> , <b>2016</b> , 11, 61-70	4.4	5
63	Toxicities and Outcomes of Ibrutinib-Treated Patients in the United States: Large Retrospective Analysis of 621 Real World Patients. <i>Blood</i> , <b>2016</b> , 128, 3222-3222	2.2	16
62	A Retrospective Analysis of Pneumocystis Jirovecii Pneumonia Infection in Patients Receiving Idelalisib in Clinical Trials. <i>Blood</i> , <b>2016</b> , 128, 3705-3705	2.2	22
61	Optimal Sequencing of Ibrutinib, Idelalisib, and Venetoclax in CLL: Results from a Large Multi-Center Study of 683 US-Patients. <i>Blood</i> , <b>2016</b> , 128, 4400-4400	2.2	2
60	Venetoclax (VEN) Monotherapy for Patients with Chronic Lymphocytic Leukemia (CLL) Who Relapsed after or Were Refractory to Ibrutinib or Idelalisib. <i>Blood</i> , <b>2016</b> , 128, 637-637	2.2	43
59	Venetoclax activity in CLL patients who have relapsed after or are refractory to ibrutinib or idelalisib.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 7519-7519	2.2	10
58	Early Progression of Disease (Blood, <b>2016</b> , 128, 3581-3581	2.2	
57	Characteristics of Patients (Pts) with Chronic Lymphocytic Leukemia (CLL) Receiving Rituximab Monotherapy in the Connect CLL Registry. <i>Blood</i> , <b>2016</b> , 128, 5941-5941	2.2	
56	Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience. <i>Blood</i> , <b>2016</b> , 128, 2199-2205	2.2	135
55	Novel agents in chronic lymphocytic leukemia. <i>Hematology American Society of Hematology Education Program</i> , <b>2016</b> , 2016, 137-145	3.1	13

54	What appears safe is sometimes not: a reason for caution. <i>Blood</i> , <b>2016</b> , 127, 2367-8	2.2	
53	The evolving role of chemoimmunotherapy in chronic lymphocytic leukemia. <i>Clinical Advances in Hematology and Oncology</i> , <b>2016</b> , 14, 756-758	0.6	
52	New oral small molecules in the treatment of chronic lymphocytic leukemia. <i>Cancer</i> , <b>2015</b> , 121, 1917-26	6.4	2
51	A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia. <i>Blood</i> , <b>2015</b> , 126, 2686-94	2.2	194
50	Preliminary Results of a Phase 2, Open-Label Study of Venetoclax (ABT-199/GDC-0199) Monotherapy in Patients with Chronic Lymphocytic Leukemia Relapsed after or Refractory to Ibrutinib or Idelalisib Therapy. <i>Blood</i> , <b>2015</b> , 126, 715-715	2.2	24
49	Favorable Outcomes in CLL Pts with Alternate Kinase Inhibitors Following Ibrutinib or Idelalisib Discontinuation: Results from a Large Multi-Center Study. <i>Blood</i> , <b>2015</b> , 126, 719-719	2.2	9
48	Prognostic testing patterns in CLL pts treated in U.S. practices from the Connect CLL registry.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 7013-7013	2.2	2
47	Reasons for Initiation of First-Line Therapy and Early Outcomes for Patients (Pts) with Rai 0/1 Chronic Lymphocytic Leukemia (CLL): An Analysis of the Connect CLL Cohort Study. <i>Blood</i> , <b>2015</b> , 126, 3284-3284	2.2	
46	Treatment Selection and Practice Patterns for the Management of High-Risk Chronic Lymphocytic Leukemia (CLL) in the US: An Analysis of the Impact of Risk Stratification on Treatment Selection from the Connect CLL Registry. <i>Blood</i> , <b>2015</b> , 126, 4483-4483	2.2	
45	Analysis of Early Mortality of Chronic Lymphocytic Leukemia (CLL) Patients Treated in US Practices in the Connect CLL Registry. <i>Blood</i> , <b>2015</b> , 126, 5270-5270	2.2	
44	Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. <i>New England Journal of Medicine</i> , <b>2014</b> , 370, 997-1007	59.2	1303
43	A phase 1, dose-escalation, pharmacokinetic and pharmacodynamic study of BIIB021 administered orally in patients with advanced solid tumors. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 445-55	12.9	35
42	A Phase 2 Study of Idelalisib Monotherapy in Previously Untreated Patients $\geq$ 5 Years with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL). <i>Blood</i> , <b>2014</b> , 124, 1986-1986	2.2	21
41	Update on a Phase 2 Study of Idelalisib in Combination with Rituximab in Treatment-Naïve Patients $\geq$ 5 Years with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL). <i>Blood</i> , <b>2014</b> , 124, 1994-1994	2.2	16
40	Demographics By Age Group (AG) and Line of Therapy (LOT) in Chronic Lymphocytic Leukemia (CLL) Patients (Pts) Treated in US Practices from the Connect CLL Registry. <i>Blood</i> , <b>2014</b> , 124, 3338-3338	2.2	2
39	Second interim analysis of a phase 3 study evaluating idelalisib and rituximab for relapsed CLL.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 7012-7012	2.2	9
38	Health-related quality of life (HRQL) impact of idelalisib (IDELA) in patients (pts) with relapsed chronic lymphocytic leukemia (CLL): Phase 3 results.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 7099-7099	2.2	3
37	Genomic Analysis of Serial Samples from CLL Patients Identifies Clonal Events Associated with Disease Progression. <i>Blood</i> , <b>2014</b> , 124, 1954-1954	2.2	

36	Patterns of Care of Aged Chronic Lymphocytic Leukemia Patients in the United States: Systematic Analysis of 457 Patients in the Connect CLL Registry. <i>Blood</i> , <b>2014</b> , 124, 4672-4672	2.2	
35	Association of health-related quality of life with gender in patients with B-cell chronic lymphocytic leukemia. <i>Supportive Care in Cancer</i> , <b>2013</b> , 21, 2853-60	3.9	21
34	Treatment of adults with acute lymphoblastic leukemia: do the specifics of the regimen matter?: Results from a prospective randomized trial. <i>Cancer</i> , <b>2013</b> , 119, 1186-94	6.4	13
33	Clinical Activity Of Idelalisib (GS-1101), a Selective Inhibitor Of PI3K In Phase 1 and 2 Trials In Chronic Lymphocytic Leukemia (CLL): Effect Of Del(17p)/TP53 Mutation, Del(11q), IGHV Mutation, and NOTCH1 Mutation. <i>Blood</i> , <b>2013</b> , 122, 1632-1632	2.2	12
32	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib and Rituximab for Previously Treated Patients with Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , <b>2013</b> , 122, LBA-6-LBA-6	2.2	3
31	Treatment of older patients with chronic lymphocytic leukemia. <i>Current Hematologic Malignancy Reports</i> , <b>2012</b> , 7, 21-5	4.4	8
30	Impact of the Conditioning Chemotherapy On Outcomes in Adoptive T Cell Therapy: Results From a Phase I Clinical Trial of Autologous CD19-Targeted T Cells for Patients with Relapsed CLL. <i>Blood</i> , <b>2012</b> , 120, 1797-1797	2.2	6
29	Variation in Health-Related Quality of Life by Line of Therapy of Patients with Chronic Lymphocytic Leukemia. <i>Blood</i> , <b>2012</b> , 120, 3926-3926	2.2	2
28	Aerobic Glycolysis Predicts Outcome in Early Chronic Lymphocytic Leukemia.. <i>Blood</i> , <b>2012</b> , 120, 2482-2482	2.2	2
27	High Dose Cytarabine and Mitoxantrone in Combination with Dasatinib As Active Induction Therapy in Adult Patients with Philadelphia Chromosome Positive (ph+) Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , <b>2012</b> , 120, 4293-4293	2.2	
26	Micafungin Versus Posaconazole Anti-Fungal Prophylaxis in Adult Patients with Acute Leukemia Undergoing Induction Chemotherapy. <i>Blood</i> , <b>2012</b> , 120, 3556-3556	2.2	
25	Variation in Health-Related Quality of Life by ECOG Performance Status and Fatigue Among Patients with Chronic Lymphocytic Leukemia. <i>Blood</i> , <b>2011</b> , 118, 4591-4591	2.2	1
24	Elevated Mitochondrial Membrane Potential in CLL Cells Is Associated with a more aggressive Natural History. <i>Blood</i> , <b>2011</b> , 118, 1765-1765	2.2	
23	Variation in Health-Related Quality of Life by Age Among Patients with Chronic Lymphocytic Leukemia. <i>Blood</i> , <b>2011</b> , 118, 2085-2085	2.2	
22	Influence of National Comprehensive Cancer Network (NCCN) Guidelines on Clinical Practice in Patients with Chronic Myelogenous Leukemia (CML) Treated At a Single Academic Medical Center. <i>Blood</i> , <b>2011</b> , 118, 4433-4433	2.2	
21	Challenges in the frontline treatment of patients with chronic lymphocytic leukemia. <i>Current Hematologic Malignancy Reports</i> , <b>2010</b> , 5, 45-51	4.4	3
20	Characteristic Proinflammatory Serum Cytokine Profiles In Patients with B-Cell Chronic Lymphocytic Leukemia. <i>Blood</i> , <b>2010</b> , 116, 3595-3595	2.2	
19	Sequential therapy with fludarabine, high-dose cyclophosphamide, and rituximab in previously untreated patients with chronic lymphocytic leukemia produces high-quality responses: molecular remissions predict for durable complete responses. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 491-7	2.2	62

18	Chemoimmunotherapy with modified dosing of fludarabine, cyclophosphamide, and rituximab shows significant clinical activity in patients with previously untreated chronic lymphocytic leukemia. <i>Current Hematologic Malignancy Reports</i> , <b>2009</b> , 4, 185-6	4.4	
17	Incorporating prognostic information into treatment decisions in chronic lymphocytic leukemia. <i>Current Oncology Reports</i> , <b>2009</b> , 11, 353-9	6.3	1
16	Pentostatin treatment combinations in chronic lymphocytic leukemia. <i>Clinical Advances in Hematology and Oncology</i> , <b>2009</b> , 7, 386-92	0.6	9
15	Pentostatin in chronic lymphocytic leukemia. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2008</b> , 4, 1217-22	5.5	18
14	Consolidation and maintenance rituximab therapy in chronic lymphocytic leukemia. <i>Current Oncology Reports</i> , <b>2008</b> , 10, 363-4	6.3	1
13	Relapsed Acute Lymphoblastic Leukemia <b>2008</b> , 275-279		3
12	Pentostatin, cyclophosphamide, and rituximab show significant clinical activity in patients with previously untreated chronic lymphocytic leukemia. <i>Current Oncology Reports</i> , <b>2007</b> , 9, 335-6; discussion 336	6.3	3
11	Pentostatin, Cyclophosphamide, Rituximab, and Mitoxantrone (PCRM): A New Highly Active Regimen for Patients with Chronic Lymphocytic Leukemia (CLL) Previously Treated with PCR or FCR.. <i>Blood</i> , <b>2007</b> , 110, 3115-3115	2.2	2
10	Advances in the treatment of chronic lymphocytic leukemia. <i>Current Hematologic Malignancy Reports</i> , <b>2006</b> , 1, 43-8	4.4	
9	Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia. <i>Journal of Clinical Oncology</i> , <b>2006</b> , 24, 1575-81	2.2	136
8	Purine analogue-based chemotherapy regimens for second-line therapy in patients with chronic lymphocytic leukemia. <i>Seminars in Hematology</i> , <b>2006</b> , 43, S44-9	4	3
7	In adult ALL, less is now more. <i>Blood</i> , <b>2006</b> , 107, 852-853	2.2	4
6	High Level T Cell Suppression Following Purine Analog Therapy for Patients with CLL Correlates with Important Clinical Benefit.. <i>Blood</i> , <b>2006</b> , 108, 2784-2784	2.2	1
5	Advances in the treatment of chronic lymphocytic leukemia. <i>Current Oncology Reports</i> , <b>2005</b> , 7, 333-8	6.3	3
4	Pentostatin, Cyclophosphamide, and Rituximab (PCR) Has Comparable Activity but Appears To Be Better Tolerated Than Fludarabine, Cyclophosphamide, and Rituximab (FCR) in Patients with Previously Treated Chronic Lymphocytic Leukemia.. <i>Blood</i> , <b>2005</b> , 106, 2127-2127	2.2	1
3	Purine analogs in leukemia. <i>Advances in Pharmacology</i> , <b>2004</b> , 51, 107-25	5.7	7
2	Pentostatin and Cyclophosphamide with or without Rituximab Has Significant Activity in Patients with Previously Treated Chronic Lymphocytic Leukemia and Other Low Grade Lymphoid Neoplasms.. <i>Blood</i> , <b>2004</b> , 104, 3484-3484	2.2	4
1	Pentostatin and cyclophosphamide: an effective new regimen in previously treated patients with chronic lymphocytic leukemia. <i>Journal of Clinical Oncology</i> , <b>2003</b> , 21, 1278-84	2.2	90

